Americas Irritable Bowel Syndrome (IBS) Treatment Market Share, Size, Trends and Global Industry 2027

14/set/2021 20:05:48 Market Research Future Contatta l'autore

Irritable Bowel Syndrome (IBS) Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Americas Forecast Till 2027

Market Highlights:

There are wide market for irritable bowel syndrome treatment in the Americas owing to increasing prevalence of patients suffering with anxiety, people feel the effects of stress in many way and one of the common symptom is  irritable bowel syndrome . Anxiety can worsen symptoms of abdominal cramps and pain and make one  feel sick in the stomach. Rising prevalence of population suffering with anxiety are the leading causes for the growth of Americas IBS market. According to updated report by Anxiety and Depression Association of America, in 2017, approximately 30 % of the adult population in North America has anxiety disorder issues. Presence of huge patient population with anxiety, have increased the chance of occurrence IBS in this region. Thus, big players are focusing on better treatment option in order to serve the patient suffering from irritable bowel syndrome .

The Americas IBS treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

According to National Center for Biotechnology Information, Irritable bowel syndrome has a prevalence of 1% to 20% worldwide, although up to 75% affected individuals never seek care. In North America, irritable bowel syndrome prevalence is 5% to 10%, affecting any age, and is 3 to 4 times more common in women.

Request Free Sample at

Americas IBS Treatment Market –Competitive Landscape

The Americas IBS treatment market is observed to be growing upwards due to key players such as Allergan Plc (Ireland), Sucampo Pharmaceuticals, Inc. (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Bausch Health Companies Inc. (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestlé (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma S.p.A. (Italy), RedHill (Israel), AstraZeneca (U.K), Ipsen Pharma (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd. (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K)..

Americas IBS Treatment Market Segmentation

The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user. On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M. On the basis of the drug type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.

The well-established market players are involved in strategic partnerships and collaborations and product updates to gain competitive advantage in this market.

In May 2018, Allergan Plc, a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc., a commercial biotech company, launched an interactive digital destination who may be suffering from IBS-D, IBS-C or CIC. The name of this website is

In January 2018, Ardelyx, Inc. announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).

In January 2018, Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies announced that the U.S. Food and Drug Administration (FDA) has approved TRULANCE (plecanatide) 3 mg tablet for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

In October 2016, Nestlé introduces ProNourish, the first nationally distributed product of its kind, designed and marketed specifically for people with digestive sensitivities. ProNourish drink is a nutritional drink that helps make following a low FODMAP diet. FODMAP is an acronym for Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols, which classifies specific types of short-chain carbohydrates that can be poorly absorbed in the small intestine, resulting in severe abdominal pain, bloating, constipation and/or diarrhea in some people.

In May 2015, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals Inc.) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., had received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan 550 mg for the treatment of IBS-D in adults.

Americas IBS Treatment Market Regional Analysis

The Americas region is divided into North America and South America.

North America holds the largest market of IBS treatment due to the well-developed healthcare infrastructure, government support, several research and development programs, widespread awareness about irritable bowel syndrome and presence of clinical laboratories.

Moreover, presence of strong economic condition, and focus of research institutions on updating technology for new irritable bowel syndrome treatments boost the growth of market in this region. Also, the countries in this region have various companies which are involved in the IBS treatment business.


To view the full report, visit at

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

blog comments powered by Disqus è un servizio offerto da Factotum Srl